KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Gross Profit (2016 - 2025)

Travere Therapeutics' Gross Profit history spans 12 years, with the latest figure at $127.1 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 76.01% year-over-year to $127.1 million; the TTM value through Dec 2025 reached $355.5 million, up 57.71%, while the annual FY2025 figure was $480.4 million, 113.1% up from the prior year.
  • Gross Profit reached $127.1 million in Q4 2025 per TVTX's latest filing, up from $38.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $127.1 million in Q4 2025 to a low of $21.3 million in Q1 2022.
  • Average Gross Profit over 5 years is $51.1 million, with a median of $40.5 million recorded in 2023.
  • Peak YoY movement for Gross Profit: plummeted 53.51% in 2022, then surged 116.94% in 2025.
  • A 5-year view of Gross Profit shows it stood at $53.4 million in 2021, then tumbled by 46.69% to $28.5 million in 2022, then surged by 42.23% to $40.5 million in 2023, then soared by 78.38% to $72.2 million in 2024, then surged by 76.01% to $127.1 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Gross Profit are $127.1 million (Q4 2025), $38.4 million (Q3 2025), and $112.9 million (Q2 2025).